Metabolic Brain Disease

, Volume 25, Issue 2, pp 177–183 | Cite as

Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson’s disease

  • Hayato Kuroiwa
  • Hironori Yokoyama
  • Hiroki Kimoto
  • Hiroyuki Kato
  • Tsutomu Araki
Original Paper


We investigated the biochemical alterations of the striatum of mice subjected to seven experimental schedules with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) treatment. The mice were treated intraperitoneally (i.p.) with MPTP (20 mg/kg in saline) four times a day at 2-hr intervals showed severe and persistent depletions of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the striatum, as compared with those (1) treated with MPTP (15 mg/kg in saline, i.p.) once a day for 14 consecutive days; (2)MPTP (30 mg/kg in saline, i.p.) twice a day for 5 consecutive days; (3) MPTP (10 mg/kg in saline, i.p.) four times a day at 1-hr intervals for 2 consecutive days; (4) MPTP (20 mg/kg in saline, i.p.) once a day for 4 consecutive days; (5) MPTP (20 mg/kg in saline, i.p.) twice a day for 2 consecutive days; (6) MPTP (20 mg/kg in saline, i.p.) twice a day for 4 consecutive days. In our Western blot analysis, furthermore, the mice that received MPTP (20 mg/kg in saline) four times a day at 2-hr intervals showed a severe decrease of the striatal tyrosine hydroxylase (TH) protein levels and a significant increase of the striatal glial fibrillary acidic protein (GFAP) levels. These results demonstrate that the model with acute MPTP treatment can cause severe neuronal damage in the mouse striatum, as compared to the model with continuous treatment with MPTP. Thus our findings may support the validity of acute MPTP treatment model for unraveling in the neurodegenerative processes in PD.


MPTP Dopaminergic system Striatum Western blot Mice 



This study was supported in part by Grant-in-Aid for Scientific Research (136700627 and 13671095) from the Ministry of Science and Education in Japan.


  1. Agid Y (1991) Parkinson’s disease: pathophysiology. Lancet 337:1321–1324CrossRefPubMedGoogle Scholar
  2. Araki T, Kumagai T, Tanaka K, Matsubara M, Kato H, Itoyama Y, Imai Y (2001a) Neuroprotective effect of riluzole in MPTP-treated mice. Brain Res 918:176–181CrossRefPubMedGoogle Scholar
  3. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001b) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-2, 3, 6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231–238CrossRefPubMedGoogle Scholar
  4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455CrossRefPubMedGoogle Scholar
  5. Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041CrossRefPubMedGoogle Scholar
  6. Hallman H, Lange J, Olson L, Stromberg I, Jonsson G (1985) Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine on brain catecholamine neurons in the mouse. J Neurochem 44:117–127CrossRefPubMedGoogle Scholar
  7. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyidine in mice. Science 224:1451–1453CrossRefPubMedGoogle Scholar
  8. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10:171–183CrossRefPubMedGoogle Scholar
  9. Jakowec MW, Petzinger GM (2004) 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned model of parkinson’s disease, with emphasis on mice and nonhuman primates. Comp Med 54:497–513PubMedGoogle Scholar
  10. Kurosaki R, Muramatsu Y, Kato H, Watanabe Y, Imai Y, Itoyama Y, Araki T (2005) Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. Eur Neuropsychopharmacol 15:57–67CrossRefPubMedGoogle Scholar
  11. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980CrossRefPubMedGoogle Scholar
  12. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 100:49–54PubMedGoogle Scholar
  13. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24:574–576CrossRefPubMedGoogle Scholar
  14. Olanow CW, Schapira AH, Agid Y (2003) Neuroprotection for Parkinson’s disease: prospects and promises. Ann Neurol 53(suppl 3):S1–S2CrossRefPubMedGoogle Scholar
  15. Ookubo M, Yokoyama H, Takagi S, Kato H, Araki T (2008) Effects of estrogens on striatal damage after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) neurotoxicity in male and female mice. Mol Cell Endocrinol 296:87–93CrossRefPubMedGoogle Scholar
  16. Ricaurte GA, Langston JW, Delanney LE, Irwin I, Peroutka SJ, Forno LS (1986) Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376:117–124CrossRefPubMedGoogle Scholar
  17. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134:57–66CrossRefPubMedGoogle Scholar
  18. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129:339–345CrossRefPubMedGoogle Scholar
  19. Takagi S, Hayakawa N, Kimoto H, Kato H, Araki T (2007) Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice. J Neural Transm 114:1553–1557CrossRefPubMedGoogle Scholar
  20. Watanabe Y, Kato H, Araki T (2008) Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson’s disease. Metab Brain Dis 23:51–69CrossRefPubMedGoogle Scholar
  21. Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T (2008) Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm 115:831–842CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Hayato Kuroiwa
    • 1
  • Hironori Yokoyama
    • 1
  • Hiroki Kimoto
    • 1
  • Hiroyuki Kato
    • 2
  • Tsutomu Araki
    • 1
  1. 1.Department of Neurobiology and Therapeutics, Graduate School and Faculty of Pharmaceutical SciencesThe University of TokushimaTokushimaJapan
  2. 2.Department of Neurology, Organized Center of Clinical MedicineInternational University of Health and Welfare HospitalTochigiJapan

Personalised recommendations